Protalix BioTherapeutics, Inc. (FRA:PBDA)

Germany flag Germany · Delayed Price · Currency is EUR
1.480
+0.030 (2.07%)
At close: Dec 4, 2025
-3.08%
Market Cap 119.59M
Revenue (ttm) 52.71M
Net Income (ttm) 4.60M
Shares Out n/a
EPS (ttm) 0.06
PE Ratio 26.01
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 215
Open 1.450
Previous Close 1.450
Day's Range 1.450 - 1.490
52-Week Range 1.140 - 2.700
Beta n/a
RSI 37.01
Earnings Date Mar 17, 2026

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell e... [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Dror Bashan
Employees 213
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol PBDA
Full Company Profile

Financial Performance

In 2024, Protalix BioTherapeutics's revenue was $53.40 million, a decrease of -18.47% compared to the previous year's $65.49 million. Earnings were $2.93 million, a decrease of -64.73%.

Financial numbers in USD Financial Statements

News

There is no news available yet.